While tissue KRAS2 mutations have been extensively investigated, the role of circulating mutant KRAS2 gene in patients with colorectal carcinoma remains obscure. The aim of the present study was to explore the prognostic significance of circulating KRAS2 gene mutational status in subjects undergoing primary treatment for colorectal cancer. Codon 12 KRAS2 mutations were examined in DNA samples extracted from the serum of 86 patients with colorectal cancer and were compared with the KRAS2 status of their primary tumors. Tissue and serum KRAS2 status was compared with other clinicopathological variables (including CEA and CA 19-9 levels) and with cancer-related survival. KRAS2 mutations were found in tissue samples of 28 patients (33%); serum KRAS2 mutations were detected in 10 of them (36%). Serum KRAS2 status was significantly associated with Dukes' stage D (p=0.001) and with preoperative CA 19-9 levels (p=0.01). At multivariate analysis, cancer-related survival was associated with Dukes' stage (p<0.0001), CEA level (p=0.02), and mutant circulating KRAS2 (p=0.01). All 7 stage D patients with serum KRAS2 mutations died of the disease within 24 months of primary treatment; cancer-related survival was significantly better in 9 stage D patients without serum KRAS2 mutations, with 5 patients (56%) alive after 24 months and 1 patient (13%) alive after 44 months. Residual disease after surgery was evident in all 7 stage D patients with mutant circulating KRAS2, and in 5 out of 9 stage D patients without serum mutations. Serum KRAS2 status may impact substantially on the management of stage D colorectal carcinoma, since it appears to correlate with prognosis in this patient subgroup. (Int J Biol Markers 2006; 21: 223-8)
INTRODUCTION
Mutations of the oncogene KRAS2 in codons 12, 13 or 61 in colon cancer tissues have been extensively investigated by numerous studies since 1986 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) , including a recent multicenter study (12) . KRAS2 oncogene mutations were found in up to 50% of colorectal carcinoma tissues. Variable rates were also found in premalignant lesions and were unrelated to age, sex, tumor site and stage. Genetic analyses have shown that tissue KRAS2 status may have prognostic significance in colorectal carcinogenesis (12) .
A long-term target in cancer research is the development of a simple blood test to detect cancers that are amenable to surgical resection and cure. Several researchers support the theory that tumor DNA is enriched in the blood (13) (14) (15) (16) (17) (18) . The use of molecular analysis of gene mutations in plasma or serum DNA as a diagnostic tool for detecting colorectal cancer was first reported by Anker (19) and successfully confirmed by several other studies (20) (21) (22) (23) (24) (25) (26) , including one of our previous studies (27) . Concordance of tissue and serum KRAS2 mutation was reported in 20-70% of colorectal cancer patients.
Since the prognostic role of KRAS2 has been seldom investigated (28) (29) , more and larger studies, with extensive follow-up, are necessary to evaluate the usefulness and possible application of circulating KRAS2 in the clinical setting.
In the present study we have attempted to clarify the clinical prognostic role of circulating KRAS2 mutations in colorectal malignancies, by prospectively analyzing tissue and serum KRAS2 codon 12 status in 86 patients with colorectal cancer.
MATERIAL AND METHODS

Patients and samples
Eighty-six patients with colorectal cancer were enrolled prospectively and consecutively during 2 separate periods (August 1997 to February 1999 and March 2000 to February 2001). All patients underwent standardized surgical treatment in the same institution (Department of Surgery, Brescia University Hospital, Brescia, Italy).
Criteria for exclusion from the study were the following: in situ colorectal carcinomas, emergency surgical procedures for occlusive or perforated colorectal cancer, synchronous colorectal or noncolorectal cancers, familial adenomatous polyposis or hereditary non-polyposis colorectal cancer, and patient's refusal to give informed consent to the study. The study cohort was composed of 46 men and 40 women with a median age of 66 years (range 41-87 years).
The following clinicopathological variables were considered: age, gender, smoking habit, stage and site of disease, type of treatment, and CEA and CA 19-9 levels (Tab. I). Tumors were staged according to the Astler-Coller modified Dukes' classification. Thirty-four patients with stage B2-C and 17 with stage D carcinoma underwent chemotherapy. Ten patients with rectal carcinomas received preoperative concomitant chemoradiotherapy. Four of the 17 stage D patients underwent resection of the metastatic tumors (one had double liver metastases at the fifth and sixth segments, one had a single liver metastasis at the third segment, one had omental metastasis and the last had distal stomach infiltration from a transverse colon cancer). One patient (stage D) died of acute myocardial infarction immediately after surgery and one patient (stage D) was lost to follow-up. Median follow-up was 41 months (range 25-72 months). Outcomes were defined as cancer-related survival and cancer-free survival.
The specificity of KRAS2 mutations in colorectal cancer was established in our previous study (27) where no KRAS2 mutations were detected in 22 specimens obtained from non-malignant diseases of the colon.
Tissue/serum sampling and DNA extraction
Tissues samples were obtained from the surgical specimen, immediately chilled on crushed ice, frozen within 30 minutes of resection, and stored at -80°C until use.
Peripheral blood (5-10 mL) was sampled before surgery, allowed to clot at room temperature for 2 hours, and centrifuged at 1000 g for 10 minutes. Serum aliquots were snap frozen and stored at -80°C until processed.
Tissue and serum DNA were extracted on QIAamp spin columns (Qiagen, Hilden, Germany) according to a previously described protocol (27) . DNA was then stored at -20°C in buffer AL (Qiagen) until use. Extraction from tumor and serum samples was performed at different times to avoid cross-contamination.
DNA analysis in serum and tissue samples
The DNA analyses were carried out using a method described elsewhere (27) . KRAS2 codon 12 gene mutations in serum samples were detected by mutant-enriched PCR (ME-PCR) in which the primer sense was designed to introduce a restriction site for the BstNI enzyme only in wildtype KRAS2 codon 12. Digestion of the first PCR amplicons by BstNI followed by a second round of PCR selectively amplified only the mutated alleles.
The ME-PCR conditions and the primer sequences used were described in our previous study (27) . Muta- (27) . All PCRs were run on a Omni-E thermal cycler (Hybaid Limited, Teddington, United Kingdom). The final digestion products were then subjected to gel electrophoresis through a 2.5% agarose or 8% acrylamide gel, stained with ethidium bromide, and visualized with UV illumination. DNA from the SW480 (homozygous for the codon 12 KRAS2 valine mutation, GTT) and LoVo (wild type for codon 12) cell lines was run with each ME-PCR or RFLP-PCR analysis, respectively, as positive and negative control. The PCR negative control was DNA-free PCR mix.
All reactions were carried out at least twice. In addition, 5 positive and 5 negative assays were run as a further control and randomly selected and submitted to a second, independent analysis which included DNA extracts, PCR and restriction endonuclease digestion. Concordant results were obtained in each case.
Serum tumor marker determination
The routinely used colorectal cancer markers carcinoembryonic antigen (CEA) and CA 19-9 were assayed. CEA and CA 19-9 were quantified by a microparticle enzyme immunoassay using the fully automated AxSYM System (Abbott Laboratories, Abbott Park, IL, USA) according to the manufacturer's instructions. Serum CA 19-9 levels were expressed as U/mL and CEA as ng/mL. The negative/positive CA 19-9 cutoff point was 37 U/mL, and the CEA cutoff points were 3 ng/mL in nonsmokers and 5 ng/mL in smokers.
Statistical analysis
Comparisons between genetic properties and clinicopathological characteristics were made using the Fisher exact test and chi-square test. Correlations between continuous variables were calculated with Spearman's correlation coefficient. The non-parametric Wilcoxon test was used to assess significant differences between the groups for continuous variables.
The biological variables (CEA, CA 19-9, age) were considered on a continuous scale, adopting a logarithmic transformation (value +1 to avoid the problem of zero values) when the distributions were positively skewed. Cox's proportional hazard model was used for univariate and multivariate analysis to evaluate the relationships between different variables and cancer-related survival. Multivariate analysis was performed only for those factors that showed significant prognostic value in univariate analysis. The multivariate analysis was limited to only 3 variables because of the limited number of events. The 3 variables chosen were the most significant in univariate analysis. Original data are shown in tables for better comprehension. All analyses were performed using the NCSS and the S-Plus statistical software.
RESULTS
Tissue and serum KRAS2 status KRAS2 codon 12 gene mutations were evaluated in tumor and serum of 86 patients with colorectal cancer. PCR analysis yielded amplified wild-type KRAS2 gene DNA from all tested samples. Thirty-three percent of the patients (28 of 86) showed KRAS2 codon 12 mutations in their tumor samples and 13% (11 of 86) in the serum samples. Ten of the 28 (36%) patients with KRAS2-mutation-positive tumors had the same mutation in their serum samples. Among the 58 patients whose primary tumors were negative for KRAS2 mutations, only one had a KRAS2 mutation in the DNA serum sample. The corresponding tumor DNA was negative for KRAS2 mutation also when ME-PCR was used and the presence of mutant DNA in the serum sample was confirmed by sequencing analysis (data not shown). In 67 of 86 patients (78%), the analysis of KRAS2 status was concordant in serum and tissue (Fisher exact test p<0.0001). No association was found between tissue KRAS2 status and clinicopathological variables including age, gender, smoking habit, stage of carcinoma, type of treatment, and preoperative CEA and CA 19-9 levels.
Serum KRAS2 status was significantly associated with disease stage (p=0.0013) and preoperative CA 19-9 levels (p=0.0133), but no association was found with any other variable. The rates of serum KRAS2 mutation were 0% of 9 stage A patients, 8% of 38 stage B patients, 5% of 22 stage C patients, and 41% of 17 stage D patients.
The CEA level was elevated in 34 colorectal cancer patients, 7 of whom (21%) showed serum KRAS2 mutation (p=0.08); CA 19-9 was elevated in 11 cases, 4 of which (36%) were also positive for KRAS2 in serum (p=0.0133) (Tab. II-III). CEA and CA 19-9 as continuous variables were both significantly associated with disease stage (p=0.0016 and p=0.0492, respectively).
KRAS2 status and survival
The median follow-up was 41 months. The patient who died of acute myocardial infarction immediately after surgery and the patient with missing follow-up data were not included in our statistical analyses.
The following variables were significantly associated with cancer-related survival in univariate analysis: CEA (p=0.0002), stage (p<0.0001), tissue KRAS2 mutation (p=0.009) and serum KRAS2 mutation (p<0.0001). CEA (p=0.02), stage (p<0.0001) and serum KRAS2 mutation (p=0.01) remained significant in multivariate analysis.
Additional subgroup analysis of survival was per-formed in stage D patients only, because of the low rate of KRAS2 mutations found in Dukes' stages A, B, and C. Cancer-related survival was 12.5% in serum KRAS2 wild-type patients and 0% in patients with mutations found in serum. Moreover, all stage D patients with positive serum KRAS2 (7/7) died of the disease within 24 months of surgery, while only 62% (5/8) of patients in the serum-KRAS2-negative group died of the disease in the corresponding period ( Fig. 1) . None of the other examined variables were significantly associated with cancerrelated survival among stage D patients; even considering the group of patients undergoing metastasectomy and those treated with palliative intent, serum KRAS2 mutation was significantly associated with cancer-related survival (p=0.02).
DISCUSSION
While numerous studies have investigated the role of KRAS2 mutation in colorectal cancer tissue, only few have evaluated the relationship between KRAS2 mutation in circulating DNA and survival (28, 29) . Our study shows that KRAS2 mutation in circulating DNA is associated with poor prognosis in colorectal cancer patients.
Several studies have been performed to establish the prognostic significance of genetic markers in colorectal cancer (30, 31) . These markers can be broadly classi- fied into oncogenes (ras, EGFR, TGF, HER2/neu), tumor suppressor genes (p53, DCC, genes involved in MSI generation, DNA hypermethylation of tumor suppressor gene promoters, p27), and genes involved in the apoptosis pathway (bcl-2, antioxidants). Their role as prognostic factors in sporadic colorectal cancer remains either controversial or to be clarified. Moreover, these biomarkers have seldom been evaluated in blood-derived samples.
The clinical relevance of tissue KRAS2 status in sporadic colorectal cancer has been investigated by a number of studies (32, 33) . From a clinical perspective, however, the use of circulating DNA assay offers several obvious advantages over tissue DNA analysis.
KRAS2 mutations are found in about one half of colorectal carcinomas (22) . In agreement with the findings of others, in our study, where only codon 12 mutations were analyzed, tissue mutations were evident in 33% of colorectal carcinomas; in 36% of patients harboring a mutant KRAS2 lesion a concordant mutation was detected in serum. The latter figure is within the reported rate of concordant tissue and serum KRAS2 mutations, which ranges from 19% to 86% (20) (21) (22) . The wide variation possibly reflects different technical approaches: plasma or serum matrices, single or multiple codon assessments, etc. Only in 1 case did we find a mutation in serum but not in tissue. This observation may be explained by the presence of multiple intratumoral clones or multiple foci of tissue with mutated genes or by a sampling error of the tumor specimen in this discrepant case.
The prognostic significance of circulating KRAS2 mutations has not yet been established because of the small sample size of most studies. In Dukes' stage A, B and C, larger series are required due to the small number of adverse events and the lower rate of concordant tissue/serum mutations. Accordingly, our study does not add any relevant insight into the prognostic value of circulating KRAS2 status in those stages.
The high proportion of circulating KRAS2 mutations in patients with metastatic disease, also seen by other authors (23) , allows us to draw several further conclusions. Circulating KRAS2 mutation in advanced colorectal carcinoma has been correlated with a poor outcome by several studies, including the present one. Moreover, preoperative serum KRAS2 status appears to be a stronger indicator of resectability than other conventional markers such as CEA or CA 19-9. No predictive criteria are available as yet to identify those patients with distant metastasis who may undergo a successful resection of both local and distant disease. In the present study, patients with a preoperative diagnosis of metastatic colorectal carcinoma and KRAS2-positive serum did not benefit from a standard primary approach in terms of radicality. Further studies are needed to define the appropriate treatment strategy in order to improve outcome in this subgroup of patients.
In conclusion, the present study shows that KRAS2 mutations detected in serum samples are a readily available tool of investigation and a reliable prognostic marker; this appears to be especially true in the metastatic stage when disease-related and disease-free survival are connected more to the biological properties of the tumor than to the current treatment options. The management of advanced colorectal cancer, either with a conventional approach or within a controlled trial, may benefit from a KRAS2-based staging strategy as this could better define the different prognostic expectations.
